- Supported exchanges /
- TWO /
- 4168.TWO
GlycoNex (4168 TWO) stock market data APIs
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under lead optimization stage; GNX202, an antibody drug currently under preclinical stage; and GNX203 and GNX204, antibody drugs currently under target validation stage. It is also involved in the development of SPD (Denosumab), a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and SEA (Aflibercept), a vascular endothelial growth factor binding fusion protein, currently under lead optimization stage for the treatment of ophthalmology and oncology. The company was incorporated in 2001 and is based in New Taipei City, Taiwan.
GlycoNex Financial Data Overview
| 25.8 | |
| 25.7 | |
| - | |
| 26 | |
| 25.7 | |
| 24-31.85 | |
| 2 792 M | |
| 108 M | |
| 10 266 K | |
| -0.5466 | |
| 0.849 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
GlycoNex Fundamental Data is available in our Financial Data APIs
- Net Revenue 10 266 K
- EBITDA -235 959 008
- Earnings Per Share -2.27
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get GlycoNex Earnings via APIs
- Latest Release 2023-05-31
- EPS/Forecast NaN
Get GlycoNex End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
